Handelsbanken Fonder AB Has $816.72 Million Holdings in Eli Lilly and Company $LLY

Handelsbanken Fonder AB lowered its stake in Eli Lilly and Company (NYSE:LLY) by 3.9% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 680,927 shares of the company’s stock after selling 27,617 shares during the period. Eli Lilly and Company makes up 2.3% of Handelsbanken Fonder AB’s investment portfolio, making the stock its 8th biggest position. Handelsbanken Fonder AB’s holdings in Eli Lilly and Company were worth $816,724,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of Eli Lilly and Company by 1.2% in the 4th quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock valued at $88,087,193,000 after acquiring an additional 1,006,885 shares during the last quarter. State Street Corp grew its position in Eli Lilly and Company by 1.8% during the 4th quarter. State Street Corp now owns 35,361,916 shares of the company’s stock worth $38,002,744,000 after acquiring an additional 635,358 shares during the last quarter. Morgan Stanley increased its holdings in Eli Lilly and Company by 2.7% in the 4th quarter. Morgan Stanley now owns 15,593,019 shares of the company’s stock worth $16,757,510,000 after purchasing an additional 407,166 shares in the last quarter. Capital World Investors raised its position in Eli Lilly and Company by 0.4% in the fourth quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock valued at $16,154,619,000 after purchasing an additional 61,851 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in Eli Lilly and Company by 10.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company’s stock valued at $16,024,022,000 after purchasing an additional 1,432,069 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The U.K. Medicines and Healthcare products Regulatory Agency approved Lilly’s Foundayo for weight loss and weight maintenance in certain adults with obesity or overweight-related health conditions. The authorization is the pill’s first European approval and gives Lilly access to a large potential market supported by its global commercial infrastructure. Eli Lilly’s GLP-1 Pill Secures First European Milestone
• Positive Sentiment: The approval also strengthens Lilly’s competitive position against Novo Nordisk in obesity drugs. Analysts and investors are increasingly focused on whether a convenient oral treatment can expand the GLP-1 market and increase patient adoption. Why Eli Lilly Topped the Market Today
• Positive Sentiment: Lilly’s latest quarterly performance remains a major support for the stock. Second-quarter revenue rose 47.7% year over year to approximately $23.0 billion, while adjusted EPS of $8.38 exceeded the $6.40 consensus estimate. Management set fiscal 2026 EPS guidance of $35.50 to $36.50, highlighting continued confidence in demand for its portfolio. Eli Lilly Posts Blowout Growth and Raises Its Outlook
• Neutral Sentiment: Investors are also weighing potential U.S. policies encouraging domestic pharmaceutical manufacturing. Lilly may be relatively well positioned if reshoring requirements favor companies with significant U.S. production capacity, although the policy details and costs remain uncertain. Eli Lilly vs. Novo Nordisk
• Neutral Sentiment: Sector rotation toward innovative healthcare companies, as investors seek alternatives to highly valued technology stocks, provided an additional supportive backdrop for Lilly. Jim Cramer Highlights Pharmaceutical Giants
• Negative Sentiment: Executive Vice President Anat Hakim sold 5,000 shares worth approximately $5.95 million under a pre-arranged Rule 10b5-1 trading plan. The transaction may attract attention, but its scheduled nature reduces its significance as a signal about Lilly’s outlook. SEC Form 4 Filing

Wall Street Analyst Weigh In

Several research firms have recently weighed in on LLY. Wells Fargo & Company boosted their price target on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the stock an “overweight” rating in a report on Thursday. Jefferies Financial Group raised their price objective on shares of Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a report on Tuesday, June 9th. The Goldman Sachs Group reiterated a “buy” rating and set a $1,283.00 target price on shares of Eli Lilly and Company in a research report on Friday, May 22nd. JPMorgan Chase & Co. boosted their target price on shares of Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an “overweight” rating in a report on Tuesday, July 7th. Finally, Leerink Partners upped their price target on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a research report on Thursday, June 25th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $1,292.18.

Eli Lilly and Company Stock Up 3.7%

Shares of NYSE LLY opened at $1,230.00 on Tuesday. The company’s 50 day moving average price is $1,162.38 and its 200-day moving average price is $1,048.95. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. Eli Lilly and Company has a 52-week low of $625.90 and a 52-week high of $1,249.45. The company has a market capitalization of $1.16 trillion, a P/E ratio of 41.28, a price-to-earnings-growth ratio of 1.38 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. During the same period in the prior year, the company posted $6.31 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities analysts forecast that Eli Lilly and Company will post 36.77 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be given a $1.73 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is 23.22%.

Insider Activity

In other news, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the transaction, the executive vice president directly owned 11,875 shares of the company’s stock, valued at $14,131,250. The trade was a 29.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is owned by corporate insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.